A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD

ConditionsHeart Failure With Preserved Ejection Fraction Coronary Microvascular Dysfunction

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorMayo Clinic

About this trial

To evaluate the effect of CS reducer implantation in patients with HFPEF and CMD on myocardial ischemia, measured by stress myocardial perfusion using cardiovascular magnetic resonance (CMR)

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18

Enrollment in main CS-reducer HFPEF study IRB# 25-002292

Disqualifiers

Metal implants that are not suitable for MRI

Inability or unwillingness of individual to give written informed consent.

Trial population

Subjects included in the main CS-reducer HFPEF study (IRB# 25-002292)

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Cardiovascular Magnetic Resonance (CMR)
Diagnostic test
Patients will consent to undergo a 50-minute non-invasive stress perfusion CMR.

Treatment groups

25 Participants

are divided into 1 treatment group

Group A: Heart Failure with a Preserved Ejection Fraction (HFpEF)1 intervention

Trial outcomes

Primary outcomes

Change in endocardial:epicardial perfusion ratio

Endocardial:Epicardial Perfusion Ratio is a measure of myocardial blood flow and will be determined by Cardiovascular magnetic resonance (CMR)

Time frame

Baseline, 6 Months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Mayo Clinic

Lead sponsor

Source ClinicalTrials.gov

Apply now